NYSE:SYKStryker Stock Price, Forecast & News

Stryker's stock was trading at $175.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SYK stock has increased by 12.3% and is now trading at $197.25. View which stocks have been most impacted by Coronavirus.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 2 sell ratings, 7 hold ratings, 17 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stryker.

Stryker is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Stryker.

Stryker Co. (NYSE:SYK) announced its quarterly earnings results on Thursday, April, 30th. The medical technology company reported $1.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.69 by $0.15. The medical technology company earned $3.59 billion during the quarter, compared to analysts' expectations of $3.45 billion. Stryker had a net margin of 14.47% and a return on equity of 24.90%. The company's quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.88 earnings per share. View Stryker's earnings history.

Stryker announced a quarterly dividend on Tuesday, May 5th. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.575 per share on Friday, July 31st. This represents a $2.30 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Monday, June 29th. View Stryker's dividend history.

27 brokers have issued 1-year target prices for Stryker's stock. Their forecasts range from $150.00 to $248.00. On average, they expect Stryker's stock price to reach $215.20 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price. View analysts' price targets for Stryker.

Media coverage about SYK stock has been trending extremely negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stryker earned a coverage optimism score of -4.6 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutStryker.

Some companies that are related to Stryker include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Masimo (MASI) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Stryker investors own include Walt Disney (DIS), Medtronic (MDT), Johnson & Johnson (JNJ), Home Depot (HD), AbbVie (ABBV), Abbott Laboratories (ABT), Visa (V), Alibaba Group (BABA), Bank of America (BAC) and NVIDIA (NVDA).

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.03%), Greenleaf Trust (5.64%), State Street Corp (3.69%), Capital Research Global Investors (2.47%), Bank of New York Mellon Corp (1.87%) and Massachusetts Financial Services Co. MA (1.66%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell and Yin C Becker. View institutional ownership trends for Stryker.

SYK stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Mackenzie Financial Corp, Nuveen Asset Management LLC, JPMorgan Chase & Co., State of Michigan Retirement System, Greenleaf Trust, UBS Group AG, and Canada Pension Plan Investment Board. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, M Kathryn Fink, Srikant M Datar, and Timothy J Scannell. View insider buying and selling activity for Stryker.

SYK stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, BlueSpruce Investments LP, Massachusetts Financial Services Co. MA, 1832 Asset Management L.P., 1832 Asset Management L.P., WCM Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., and Invesco Ltd.. View insider buying and selling activity for Stryker.

Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYK stock can currently be purchased for approximately $197.25.

Stryker has a market capitalization of $73.94 billion and generates $14.88 billion in revenue each year. The medical technology company earns $2.08 billion in net income (profit) each year or $8.26 on an earnings per share basis. Stryker employs 40,000 workers across the globe.

The official website for Stryker is www.strykercorp.com.

Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]